

Zydus Announces Settlement of a DELZICOL[®] (mesalamine) Patent Litigation

Ahmedabad, Dec. 3, 2016

Zydus Cadila, an innovation-driven global pharmaceutical company, announced that the patent litigation relating to Allergan's DELZICOL[®] (mesalamine) has been settled. As a result of the settlement, and if approved by FDA, its US subsidiary, Zydus Pharmaceuticals (USA) Inc., will be able to market its generic version of DELZICOL[®] in the United States beginning on March 1, 2020, or earlier under certain circumstances.

###